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ABSTRACT 
Nephropathy associated with type 2 diabetes is the single most common cause of end-stage 
renal disease. The aim of the present study was to evaluate the preventive effect of ethanolic 
extract of Embelia ribes fruit (EER) against high fat diet (HFD) and low dose streptozotocin 
(STZ)-induced diabetic nephrotoxicity in Wistar rats. HFD-fed and low dose STZ (35 mg/kg, 
i.p)-induced diabetic rats were treated with EER (100 and 200 mg/kg/day) for 21 days while 
continuing on HFD. Preventive effects of EER were demonstrated by significant reduction 
(p< 0.01) in body weight gain, fasting blood glucose, blood pressure, serum lactate dehydro-
genase (LDH), creatinine, alkaline phosphatase (ALP), total cholesterol and triglyceride lev-
els, while elevation in serum albumin and total protein levels. Insulin sensitizing effects were 
seen during oral glucose tolerance testing. Further, EER treatment significantly (p< 0.01) de-
creased the kidney thiobarbituric acid-reactive substance (TBARS) levels, while increasing 
the superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) levels in diabetic 
rats. Histological studies of kidney also supported the experimental findings. Taken together, 
our data suggest that EER attenuates renal injury in type 2 diabetic rats, possibly by im-
provement in glucose and lipid metabolism, enhancement of insulin sensitivity, blood pres-
sure lowering, and inhibition of lipid peroxidation process. 
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INTRODUCTION 
Nephropathy is one of the major com-
plications of both type 1 and type 2 diabetes 
mellitus, and the morbidity and mortality 
due to diabetic nephropathy (DN) continues 
to increase in industrialized nations (Bala-
kumar et al., 2009). Nephropathy associated 
with type 2 diabetes is much more wide-
spread and account for about one third of 
all patients requiring kidney replacement 
therapy in western countries (Ruggenenti 
and Remuzzi, 2000). DN is characterized 
by a progressive increase in albuminuria, 
proteinuria, reduction in glomerular filtra-
tion rate (GFR), hypertension, and a high 
risk of cardiovascular morbidity and mor-
tality (Balakumar et al., 2009). Risk factors 
for DN include hyperglycemia, insulin re-
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sistance, hypertension, genetic predisposi-
tion, glomerular hyperfiltration, proteinuria, 
advanced glycation end-products, reduced 
nephron number and lipid disorders 
(Cooper, 2001; Hall, 2006). Hyperglycemia 
generates more reactive oxygen species 
(ROS) and promotes oxidative stress, which 
is known to play crucial role in the patho-
genesis of DN (Alhaider et al., 2011). Fur-
ther, obesity and insulin resistance contrib-
ute to the progression of renal disease 
(Knight and Imig, 2007). Thus, metabolic 
and hemodynamic factors should be con-
trolled in order to prevent the progression 
of DN. 
Currently available therapeutic options 
to treat patient with DN includes agents like 
angiotensin converting enzyme inhibitors, 
angiotensin AT1 receptor blocker and few 
antioxidants, which have been shown to 
improve the function of diabetic kidney to 
some extent (Balakumar et al., 2009). 
Therefore, efforts are being made to explore 
new promising therapeutic interventions to 
treat DN. Recently, herbs and/or natural 
products have been highlighted as an alter-
native to the current management of DN 
(Shafi et al., 2012). 
Embelia ribes Burm. (family Myrsina-
ceae), a large climbing shrub with long 
slender brittle stem, long internodes, terete 
branches, is sparsely distributed in the 
moist deciduous forests of the Western 
Ghats in India, Sri Lanka, Malaysia, South 
China and Kenya. Embelin (2,5-dihydroxy-
3-undecyl-1,4-benzoquinone, Figure 1) is a 
major bioactive constituent and marker 
compound in E. ribes fruit (Madhavan et 
al., 2011). The fruit is bitter in taste, and 
has been used to treat fever, inflammatory 
diseases, and a variety of gastrointestinal 
ailments for thousands of years. The plant 
is popularly known as ‘vidanga’ in the Indi-
an system of medicine ‘Ayurveda’ and it is 
an ingredient in many Ayurvedic prepara-
tions. Earlier studies in our laboratory 
showed that ethanolic fruit extract of 
E. ribes possesses antihyperglycemic, lipid 
lowering and antioxidant properties in insu-
lin-deficient diabetes in rat models, induced 
by high dose of streptozotocin (Bhandari et 
al., 2002, 2007). However, therapeutic po-
tential of E. ribes for its preventive effect 
on diabetic nephrotoxicity in type 2 diabetic 
rats is unclear. Several animal models have 
been used to assess the pathogenesis of dia-
betes and associated complications. How-
ever, rats fed a high-fat diet (HFD) and giv-
en a low dose of streptozotocin (STZ) de-
velop type 2 diabetes with insulin re-
sistance, hyperinsulinemia, hyperglycemia, 
hyperlipidemia, hypertension, proteinuria 
and kidney lesions, similar to human type 2 
diabetes and nephropathy where multiple 
factors appear to act synergistically to ac-
celerate kidney damage (Danda et al., 
2005). Hence, in the present work, we in-
vestigated the preventive role of ethanolic 
extract of E. ribes (EER) fruits on diabetic 
nephrotoxicity using a model of type 2 dia-
betes induced by HFD and low dose STZ in 
Wistar rats. 
Figure 1: Chemical structure of embelin (2,5-di-
hydroxy-3-undecyl-1,4-benzoquinone) 
 
 
MATERIALS AND METHODS 
Chemicals 
STZ was purchased from Sigma Al-
drich, St. Louis, MO, USA. Commercially 
available standard kits were used for the 
determination of insulin (ultra sensitive rat 
insulin ELISA kit, Crystal Chem Inc., IL, 
USA), total cholesterol, triglycerides, alka-
line phosphatise (ALP), creatinine, albumin 
and total protein (Span Diagnostics Ltd., 
Surat, India), and lactate dehydrogenase 
(LDH; Crest Biosystems, Goa, India). All 
other chemicals were commercial products 
of analytical reagent grade. 
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Plant material and preparation of  
extraction 
The berries of E. ribes were purchased 
from North Eastern India Ayurveda 
Research Institute, Barsjoi, Guwahati, 
Assam, India, and authenticated by Dr. H. 
B. Singh, Head, Raw Materials and 
Herbarium, National Institute of Science 
Communication and Information Resources 
(NISCAIR), New Delhi, India, where a 
voucher specimen has been deposited (No. 
NISCAIR/RHMD/Consult/-2010-11/1500/ 
98, dated 26 August, 2010). 
The dried and powdered fruits of E. 
ribes were Soxhlet extracted with 70 % 
ethanol in a Soxhlet apparatus for 72 h. The 
solvent was removed under reduced 
pressure to give a dry extract, 8.4 % w/w 
yield with respect to the crude material and 
stored at -20 °C until the experiment. 
 
HPTLC and HPLC analysis of extract 
Phytochemical analysis and high 
performance thin layer chromatography 
(HPTLC) finger printing data of EER has 
been previously published (Ansari and 
Bhandari, 2008). The HPLC analysis of 
EER was carried out by the methodology of 
Shelar et al. (2009) on HPLC system 
(Waters Corporation, USA) equipped with 
Millennium Chromatography software 
version 2.15 and the chromatographic 
separations were performed using a 
Hyperchrome Column (250 mm×4.6 mm), 
with a flow rate of 1 ml/min and a sample 
size of 10 µl. The mobile phase used was 
methanol (A) and 0.1 % trifluoroacetic acid 
(B) with a ratio of 88:12 (A:B (v/v)). The 
flow rate was set 1 ml/min and sample 
analysis performed at wavelength 288 nm 
using photodiode array (PDA) detector at 
ambient temperature. The chromatographic 
peaks of the EER were confirmed by 
comparing its retention time and UV 
spectra with corresponding reference 
standard embelin. The result was obtained 
by comparison of peak area (at 288 nm) of 
EER with that of embelin. 
 
Experimental animals 
The male Wistar rats (150-200 g) were 
procured from central animal house facility 
of Hamdard University, New Delhi, India. 
Rats were housed in clean solid bottom, 
stainless steel mesh polypropylene rat cages 
and maintained under controlled room 
temperature (22 ± 2 °C) and humidity (55 ± 
5 %) with 12:12 h light and dark cycle. All 
the rats had free access to standard rat feed 
and water ad libitum. The study was 
approved by the Institutional Animal Ethics 
Committee of Jamia Hamdard, New Delhi, 
India, (Approval No. 316) and performed as 
per the guidelines of Committee for the 
Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), India. 
Rats were allowed to acclimate to the 
experimental environment for 1 week 
before dietary intervention was initiated. 
 
High fat diet and low dose streptozotocin-
induced type 2 diabetes 
The rats were allocated into two dietary 
regimens by feeding either standard rat feed 
or HFD (from National Institute of 
Nutrition (NIN), Hyderabad, India) ad 
libitum, respectively, for the initial period 
of 2 weeks (Srinivasan et al., 2005). The 
composition of HFD was described 
elsewhere (Chaudhari et al., 2012). After 
the 2 weeks of dietary manipulation, the 
group of rats fed by HFD was injected 
intraperitoneally (i.p.) with low dose of 
STZ (35 mg/kg), while the respective 
control rats were given vehicle citrate 
buffer (pH 4.4) in a dose volume of 
1 ml/kg, i.p. The fasting blood glucose was 
measured 3 days after the vehicle or STZ 
injection. The rats with the fasting blood 
glucose ≥200 mg/dl were considered dia-
betic and selected for further pharma-
cological studies. The rats were allowed to 
continue to feed on their respective diets 
until the end of the study. 
In this experiment, a total of 40 rats (10 
normal; 30 HFD+STZ-induced diabetic 
rats) were used and were divided into four 
groups of 10 rats in each as follows:  
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Group I: normal control rats administered 
1 % gum acacia in saline daily (NC)  
Group II: diabetic control rats administered 
1 % gum acacia daily (DC)  
Group III: diabetic rats administered 
ethanolic extract of E.ribes [100 mg/kg, 
body weight (bw)] (EER100)  
Group IV: diabetic rats administered 
ethanolic extract of E. ribes (200 mg/kg, 
bw) (EER200).  
All the drugs were administered orally 
via a standard orogastric cannula everyday 
for the period of 21 days. Diet and water 
were provided ad libitum. Body weight was 
measured weekly. At the end of 21 days, 
the diets were removed from the cages 12 h 
before the animals were euthanized. Blood 
samples were collected by the retro-orbital 
method and centrifuged at 1500 g for 
15 min to obtain serum. After the collection 
of blood, the rats were euthanized, kidney 
was excised immediately, rinsed with 
phosphate buffer saline, and weighed. The 
serum and kidney samples were stored 
at -70 °C until analysis. 
  
Measurement of blood pressure  
Mean arterial blood pressure was 
measured by Non-Invasive Blood Pressure 
Recorder on last day of the study using rat 
tail-cuff method (Kent Scientific Corpor-
ation, USA). 
 
Fasting blood glucose measurements 
Fasting blood glucose levels were 
measured weekly on lateral tail vein blood 
samples using an ACCU-Check glucose 
meter (Roche Diagnostics GmbH, Mann-
heim, Germany) throughout the treatment 
period. 
 
Oral glucose tolerance test (OGTT) 
OGTT was performed 3 weeks after 
treatment. Rats were orally gavaged with 
2 g/kg body weight of glucose dissolved in 
water (40 % w/v) after overnight fasting. 
Blood samples were collected from tail 
veins after 0, 15, 30, 60 and 120 min. 
Serum insulin levels were measured at the 
indicated time points using ultra sensitive 
rat insulin ELISA kit (Crystal Chem Inc., 
IL, USA). The results were expressed as 
area under the curve (AUC0-120 min). 
 
Determination of the serum biochemical 
parameters 
Serum levels of insulin, total chole-
sterol, triglycerides, LDH, ALT, creatinine, 
albumin and total protein were measured 
using the commercially available standard 
kits and according to manufacturer’s 
instructions. 
Insulin sensitivity was assessed by 
computing the homeostatic model assess-
ment (HOMA) by following formula: 
HOMA= Insulin (µU/ml) × glucose (mM) / 
22.5 
 
Determination of lipid peroxidation and 
free radical scavenging activity in kidney 
tissue 
A portion of the kidney was minced and 
homogenized (10 % w/v) for determination 
of lipid peroxidation by thiobarbituric acid 
reactive substances (TBARS) (Ohkawa et 
al., 1979), reduced glutathione (GSH) 
(Calberg and Mannerviek, 1975), super-
oxide dismutase (SOD) (Marklund and 
Marklund, 1974), and catalase (CAT) 
(Caliborne, 1985) activities. The protein 
content of the samples was measured to the 
method of Lowry et al. (1951). 
 
Histopathological examinations 
For histological examination, the kidney 
was collected and fixed in 10 % neutral 
buffered formalin, embedded in paraffin. 
Standard sections of 5 μm thickness were 
cut, which were then stained with hemato-
xylin and eosin (H&E), and examined by 
light microscopy. 
 
Statistical analysis 
Data are expressed as the mean ± 
standard error of the mean (SEM). The 
statistical significance of difference 
between the mean values for the treatment 
groups was analyzed by ANOVA (analysis 
of variance) followed by Dunnett’s t-test 
using Graph pad InStat® version 3.06 
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(Graph Pad Software, San Diego, CA, 
USA). Values of p< 0.05 were considered 
significant.  
 
RESULTS 
HPLC analysis of EER extract 
The presence of embelin in EER was 
established by HPLC and quantified as 
3.3 % (Figure 2). 
 
Effect of EER on body weight gain, kidney 
weight and kidney weight/body weight  
ratio 
A statistically significant (p< 0.01) 
decrease in body weight gain of HFD-fed 
and low dose STZ treated group (i.e. DC 
group) was observed as compared to NC 
group. Treatment with EER for 21 days at 
100 and 200 mg/kg/day of body weight by 
the oral route significantly (p< 0.01) 
decreased the body weight gain compared 
to the body weight gain of DC group. 
Moreover, the kidney weight evaluation at 
the end of the study revealed that there was 
remarkable elevation in kidney weights in 
DC group as compared to NC group. 
Kidney weight body weight ratio was 
significantly (p< 0.01) higher in DC group 
compared with the NC group. In contrast, 
kidney weights and kidney weight/body 
weight ratio were significantly (p< 0.05) 
lower in the EER100 and EER200 treated 
groups compared with the DC group (Table 
1). 
 
 
 
 
  
Figure 2: HPLC chromatograms of Embelia ribes ethanol extract (A) and the standard embelin (B) 
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Table 1: Effect of EER on body weight gain, kidney weight and mean arterial blood pressure in HFD-
fed and low dose STZ-induced type 2 diabetes in Wistar rats 
Groups NC DC EER100 EER200 
Body weight gain 
(g) 47.49 ± 1.53 38.67 ± 1.65** 24.71 ± 1.94
## 20.20 ± 1.86## 
Kidney weight (g) 0.68 ± 0.007 1.49 ± 0.044** 1.36 ± 0.012# 1.33 ± 0.057# 
(Kidney weight/ 
body weight) × 100 0.271 ± 0.002 0.481 ± 0.007** 0.464 ± 0.004
# 0.459 ± 0.001## 
Mean arterial blood 
pressure (mm Hg) 95.63 ± 0.80 121.70 ± 0.80** 113.03 ± 0.68
## 105.90 ± 0.68## 
All values were expressed as Mean  SEM, (n=10); *P< 0.05, **P< 0.01 as compared to NC group; 
#P<0.05, ##P< 0.01 as compared to DC group 
 
 
Effect of EER on blood pressure 
A statistically significant (p< 0.01) 
increase in mean arterial blood pressure 
was observed in DC group compared to the 
NC group by 3 weeks after induction of 
diabetes. EER (100 and 200 mg/kg) 
restored the elevated mean arterial blood 
pressure in DC group (Table 1). 
 
Effect of EER on fasting blood glucose 
levels 
Before treatment, fasting blood glucose 
levels of EER100 and EER200 were 
comparable with DC group (Table 2, week 
0). The levels of fasting blood glucose in 
EER100 and EER200 treated groups 
reduced by 35 % and 48 % after 1 week, by 
43 % and 54 % after 2 weeks, and by 54 % 
and 65 % after 3 weeks, respectively when 
compared with DC group (p< 0.01). 
Effect of EER on insulin release in  
response to OGTT 
Rats in diabetic control group (DC) had 
significantly lower (P< 0.01) serum insulin 
levels at all the time points i.e. 0, 15, 30, 60 
and 120 minutes post-oral glucose loading 
as compared to normal control group (NC). 
Compared to the diabetic control (DC), 
treatment with EER100 and EER200 
resulted in a significant increase (p< 0.05 
and p< 0.01, respectively) in the serum 
insulin levels in Wistar rats at all the time 
points (Figure 3A). The AUC0-120 min of 
insulin during the OGTT was significantly 
lower (p< 0.01) in the DC group as 
compared to NC, EER100 and EER200 
group (Figure 3B). 
 
 
 
 
 
Table 2: Effect of EER on fasting blood glucose levels in HFD-fed and low dose STZ-induced type 2 
diabetes in Wistar rats 
 Blood glucose (mg/dl)
Groups 0 week 1st week 2nd week 3rd week 
NC 107.3 ± 0.7 111.9 ± 1.5 109.2 ± 1.7 110.2 ± 1.6 
DC 333.0 ± 21.9** 331.3 ± 10.5** 341.2 ± 12.5** 365.6 ± 9.5** 
EER100 330.4 ± 19.9 215.0 ± 3.3## 191.6 ± 2.9## 166.8 ± 0.8## 
EER200 337.4 ± 17.2 171.0 ± 4.4## 155.3 ± 2.4## 124.6 ± 1.8## 
All values were expressed as Mean  SEM, (n=10); *P< 0.05, **P< 0.01 as compared to NC group; 
#P<0.05, ##P< 0.01 as compared to DC group 
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Figure 3A: Effect EER treatment on serum 
insulin levels in response to an oral glucose 
challenge in HFD-fed and low dose STZ-
induced type 2 diabetes in Wistar rats 
 
All values were expressed as mean  SEM, (n=10);  
*P< 0.05, **P< 0.01 as compared to NC group; #P<0.05, 
##P< 0.01 as compared to DC group 
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Figure 3B: Effect EER treatment on area under 
curve (AUC 0-120 min) of serum insulin levels in 
response to an oral glucose challenge in HFD-
fed and low dose STZ-induced type 2 diabetes 
in Wistar rats 
 
All values were expressed as mean  SEM, (n=10);  
*P< 0.05, **P< 0.01 as compared to NC group; #P<0.05, 
##P< 0.01 as compared to DC group 
 
 
Effect of EER on biochemical parameters 
Serum insulin levels at the end of the 
study period are shown in Figure 4. In 
comparison to NC group, HFD-fed and low 
dose STZ treated diabetic rats showed 
significantly (p< 0.01) decreased serum 
insulin levels. EER treatment in diabetic 
rats at both doses showed significant (p< 
0.01) increase in serum insulin levels. 
Insulin resistance in diabetic rats (DC 
group) was indicated by higher HOMA 
values as compared to normal control rats 
(NC group). Rats treated with EER100 and 
EER200 showed improved insulin sen-
sitivity as compared to DC group (Figure 
5). 
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Figure 4: Effect EER treatment on serum 
insulin levels in HFD-fed and low dose STZ-
induced type 2 diabetes in Wistar rats. 
 
All values were expressed as Mean  SEM, (n=10);  
*P< 0.05, **P< 0.01 as compared to NC group; #P<0.05, 
##P< 0.01 as compared to DC group 
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Figure 5: Effect EER treatment on homeostasis 
model assessment of insulin resistance 
(HOMA-IR) in HFD-fed and low dose STZ-
induced type 2 diabetes in Wistar rats 
 
All values were expressed as mean  SEM, (n=10);  
*P< 0.05, **P< 0.01 as compared to NC group; #P<0.05, 
##P< 0.01 as compared to DC group 
 
 
Oral administration of EER at 100 and 
200 mg/kg dose for 21 days in diabetic rats 
significantly (p< 0.01) reduced serum 
triglycerides by 30 and 44 %, and total 
cholesterol by 15 and 24 %, respectively as 
compared to DC rats (Figure 6). The HFD-
fed and low dose STZ-induced type 2 
diabetic rats showed a significant (p< 0.01) 
increase in the levels of serum LDH, 
creatinine, ALP and a significant (p< 0.01) 
decrease in the levels of total protein and 
albumin when compared to NC rats. 
Treatment with EER at both the doses 
caused a significant reversal of all these 
changes towards the normal (Table 3). 
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Table 3: Effect of EER on serum biochemical parameters in HFD-fed and low dose STZ-induced type 
2 diabetes in Wistar rats 
Groups NC DC EER100 EER200 
LDH (U/L) 158.7 ± 6.5 297.9 ± 8.1** 218.6 ± 5.3## 182.1 ± 3.7## 
Creatinine (mg/dl) 0.268 ± 0.03 0.573 ± 0.09** 0.383 ± 0.03## 0.313 ± 0.02## 
ALP (IU/L) 169.9 ± 7.8 356.6 ± 41.8** 269.1 ± 4.5## 227.6 ± 5.4## 
Albumin (g/dl) 3.80 ± 0.12 2.68 ± 0.11** 3.21 ± 0.15## 3.48 ± 0.17## 
Total protein (g/dl) 6.09 ± 0.35 4.37 ± 0.27** 5.60 ± 0.12## 5.82 ± 0.23## 
All values were expressed as mean  SEM, (n=10); *P< 0.05, **P< 0.01 as compared to NC group; 
#P<0.05, ##P< 0.01 as compared to DC group 
 
 
Effect of EER on kidney oxidative stress 
biomarkers 
TBARS levels were determined by 
evaluating kidney malondialdehyde (MDA) 
content. Rats in DC group showed a 
significant (p< 0.01) increase in kidney 
TBARS content by 2.7-fold as compared 
with those in NC group. Administration of 
EER at 100 mg/kg dose caused a significant 
decrease in kidney TBARS content by 1.5-
fold while 200 mg/kg dose showed 1.9-fold 
reduction as compared to DC group. As 
shown in Table 4, the levels of kidney 
GSH, SOD, and CAT in DC group were 
decreased by 1.52-, 1.56, and 3.93-fold, 
respectively as compared to the NC group. 
Administration of EER at 100- and 
200 mg/kg dose for 21 days significantly 
(p< 0.01) increased in kidney GSH (1.57- 
and 1.62-fold), SOD (1.28- and 1.36-fold), 
and CAT (2.66- and 3.22-fold) levels, 
respectively, when compared with DC 
group. 
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Figure 6: Effect EER treatment on serum total 
cholesterol and triglyceride levels in HFD-fed 
and low dose STZ-induced type 2 diabetes in 
Wistar rats 
 
All values were expressed as mean  SEM, (n=10);  
*P< 0.05, **P< 0.01 as compared to NC group; #P<0.05, 
##P< 0.01 as compared to DC group 
 
 
 
Table 4: Effect of ethanolic E. ribes extract on kidney oxidative stress parameters in HFD-fed and low 
dose STZ-induced type 2 diabetes in Wistar rats 
Groups NC DC EER100 EER200 
TBARS 
(nmol MDA/mg 
protein) 
1.10 ± 0.05 3.06 ± 0.09** 1.97 ± 0.05## 1.55 ± 0.03## 
GSH 
(μmol of P liberated 
/min/mg protein) 
5.46 ± 0.11 3.60 ± 0.14** 5.66 ± 0.12## 5.84 ± 0.14## 
SOD 
(U/mg protein) 8.98 ± 0.19 5.75 ± 0.29** 7.34 ± 0.16
## 7.82 ± 0.24## 
CAT 
(nmol of H2O2 /min/ 
mg protein) 
47.59 ± 3.03 12.11 ± 1.15** 32.21 ± 0.55## 39.03 ± 1.05## 
All values were expressed as mean  SEM, (n=10); *P< 0.05, **P< 0.01 as compared to NC group; 
#P<0.05, ##P< 0.01 as compared to DC group 
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Effect of EER on histopathological  
analysis of kidney 
In the histopathological studies, kidney 
sections in NC group showed glomeruli and 
proximal convoluted tubules. The kidney 
sections of diabetic rat showed congestion, 
proteinuria, haemorrhage, and tubular 
degeneration. However, EER at 100 and 
200 mg/kg treated diabetic rats kidney 
showed glomeruli and tubules without 
proteinuria and haemorrhage (Figure 7). 
 
 
 
 
 
 
 
 
Figure 7: Histological changes in kidney of 
experimental rats. (A) Normal control group 
(NC), kidney shows glomeruli and proximal 
convoluted tubules; (B) Diabetic control group 
(DC), kidney shows tubular degeneration and 
congestion of capillaries; (C) Ethanolic extract 
of E. ribes (100 mg/kg) treated group 
(EER100), shows normal histological structure; 
(D) Ethanolic extract of E. ribes (200 mg/kg) 
treated group (EER200), shows normal 
architecture of kidney 
 
DISCUSSION 
In this study, the effects of EER on 
diabetic nephrotoxicity were assessed using 
a HFD and low dose STZ-induced type 2 
diabetic rat model. This rat model exhibits 
hyperglycemia, hyperlipidemia and insulin 
resistance that would closely reflect the 
natural history and metabolic characteristics 
of human type 2 diabetes (Srinivasan et al., 
2005). Further, Danda et al. (2005) showed 
that type 2 diabetic rats (induced by feeding 
HFD and low dose STZ) developed more 
pronounced kidney lesions than type 1 
diabetic (induced by high dose STZ 
injection) rats. Hence, this is an appropriate 
experimental model to examine the effect 
of various therapeutic agents on diabetic 
nephrotoxicity. 
The presence of embelin in EER was 
established by HPLC and quantified as 
3.3 % (Figure 1). Embelin, a naturally 
occurring alkyl substituted hydroxy 
benzoquinone, is considered one of the 
major bioactive constituents and marker 
compounds in E. ribes fruits (Madhavan et 
al., 2011). 
A
B
C
D
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As overweight or obesity in type 2 
diabetes can exacerbate metabolic 
abnormalities, there is need for weight loss 
(Krentz, 2007). In fact, lifestyle 
interventions to promote weight loss are 
generally considered first-line therapy for 
type 2 diabetes. In our study, diabetic rats 
treated with EER at 100 and 200 mg/kg 
showed a significant decline in body weight 
gain, kidney weight, and kidney 
weight/body weight ratio, suggesting a 
weight reducing effect of extract. Herein, 
we have corroborated previous finding 
showing that embelin (active constituent of 
E. ribes) decreased body weight in HFD-
fed obese rats (Chaudhari et al., 2012). 
Hypertension has been reported to 
aggravate DN through its additive 
glomerular hypertension (Hostetter et al., 
1982). Moreover, hypertension is also 
associated with an elevation of ROS and 
reducing antioxidant levels (Tomohiro et 
al., 2007). EER (100 and 200 mg/kg) 
treatment for 21 days produced a significant 
reduction in mean arterial blood pressure in 
diabetic rats. Thus, EER may be beneficial 
in patients with DN as optimal control and 
maintenance of normal sugar and blood 
pressure level are vital to prevent the 
progression of DN (Balakumar et al., 2009). 
Hyperglycemia is an important causal 
factor in mediating the development and 
progression of DN (Roy et al., 2010). It also 
activates multiple signalling pathways that 
leads to increased generation of reactive 
oxygen species (ROS), which can damage 
the kidney, pancreatic β-cells, and induce 
insulin resistance (Brownlee, 2001; Aragno 
et al., 2004). In order to clarify the 
antihyperglycemic effect of EER in type 2 
diabetic rats, we have measured fasting 
blood glucose levels at weekly interval for 
the period of 3 weeks. The present fasting 
blood glucose data of diabetic rats receiving 
EER (100 and 200 mg/kg) daily for the 
period of 21 days clearly demonstrates that 
EER at both the doses could control 
hyperglycemia, the key feature of diabetes 
mellitus. The observed antihyperglycemic 
effect of EER is supported by our previous 
reports (Bhandari et al., 2002, 2007). It 
appears likely that EER effect on diabetic 
renal injury is due to improvement in 
glycemic control.  
Insulin plays a homeostatic role in 
normal kidney function. However, insulin-
resistance has been associated with 
alterations in glomerular hemodynamics 
and renal damage (Knight and Imig, 2007). 
Hence, insulin sensitizing drugs may have 
preventive effects on renal injury in obesity 
and insulin resistance. We found that HFD-
fed and low dose STZ-treated diabetic rats 
had frank hyperglycemia in the presence of 
comparable amount of serum insulin 
concentrations, indicated the persistence of 
insulin resistance. The presence of insulin 
resistance is further indicated by higher 
values of HOMA in diabetic control group. 
The HOMA values were significantly 
(p< 0.01) decreased in EER100 and 
EER200 treated groups when compared 
with diabetic control (DC) group. Insulin 
sensitizing capability of EER was further 
confirmed by serum insulin concentration-
time curve for 120 min (AUC0-120 min) in 
OGTT. Compared to diabetic control, EER 
at 100 and 200 mg/kg treated group showed 
a clear increase in the early-phase serum 
insulin in Wistar rats. Serum insulin levels 
at all the time points and AUC0-120 min were 
significantly (p< 0.05) higher in EER 
treated group compared to diabetic control 
(DC) group, indicating the insulin 
sensitizing potential of EER. Furthermore, 
the circulating serum insulin levels 
observed in the present study revealed 
significant effect of EER on insulin 
secretion in HFD-fed and low dose STZ-
induced diabetic rats during the 3 weeks of 
treatment period. These diabetic rats had 
significantly lower circulating serum 
insulin levels, whereas EER treated diabetic 
rats had significantly increased serum 
insulin levels. Thus, an important benefit of 
EER in treating diabetic renal injury is to 
improve glycemic control by attenuating 
insulin resistance. 
The present study also showed that EER 
treatment effectively improved lipid 
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metabolites including total cholesterol and 
triglycerides levels in diabetic rats. It is 
well known that impaired insulin action 
results in hyperlipidemia (Reaven, 2005). 
Studies have shown that DN is resulted 
from elevated renal local lipid accumulation 
(Yokoyama et al., 2010). Regulation of 
serum or tissue lipid levels leads to 
decrease in the risk of lipid-induced 
glomerular injury (Dominguez et al., 2000). 
It is possible that EER improved lipid 
metabolites by enhancement of insulin 
sensitivity in the present study.  
Diabetes is the leading cause of chronic 
kidney disease (CKD), which makes 
estimation of renal function crucial. To 
demonstrate an alteration of renal function 
in diabetic rats, LDH, creatinine, ALP, 
albumin and total protein levels were 
measured in serum. Increased levels of 
LDH are found in renal, hepatic, pulmonary 
and cardiovascular diseases. Currently, 
measuring urine albumin excretion and 
creatinine (for estimation of GFR) remains 
the most effective screening method for the 
early detection of DN (Kramer, 2004). ALP 
levels are significantly increased in human 
patients suffering from renal insufficiency 
(Sanchez Navarro et al., 2002). Further, it 
has been shown that ALP-enzyme-
regulating gene is expressed not only in the 
liver but also at high level in the kidneys 
too (Lindblom et al., 2007). The decrease in 
total protein and albumin levels in diabetic 
rats may be due to microproteinuria and 
albuminuria and/or may be due to increased 
protein catabolism. We have shown that 
treatment with EER significantly prevented 
enhanced levels of serum LDH, creatinine 
and ALP as well as alteration in serum 
albumin and total protein, valuable markers 
of renal disease. The biochemical changes 
were correlated with a histopathological 
examination, which revealed that HFD- and 
low dose STZ caused a marked damage in 
renal structure showing congestion, 
proteinuria, haemorrhage, and tubular 
degeneration (Figure 7B). This finding is 
supported by previous pathological study 
on the pathological feature of 
nephrotoxicity (Danda et al., 2005). 
Treatment with EER prevented such 
alterations and protected the histological 
aspects of kidney. 
Studies have shown that there is a close 
relationship between hyperglycemia, 
increase of ROS, and lipid peroxidation 
(LPO) in the progression of DN (Ha and 
Kim, 1999). Kidney is one of the organs 
that are vulnerable to oxidative damage 
caused by free radicals. ROS could react 
with polyunsaturated fatty acids which lead 
to lipid peroxidation. Malondialdehyde 
(MDA) is a by-product of LPO and reflects 
the degree of oxidation in the body 
(Ohkawa et al., 1979). In the present study, 
kidney TBARS level determined by 
evaluating MDA content were decreased 
after 21 days of EER treatment at both the 
doses 100 mg/kg and 200 mg/kg dose in 
HFD and low dose STZ-induced diabetic 
rats. Further, in our study, the activities of 
GSH (a major endogenous antioxidant), 
SOD and CAT (scavenger of free radicals) 
were significantly decreased in HFD fed 
and low dose STZ-induced diabetic rats as 
reported earlier (Zhang et al., 2010; 
Veerapur et al., 2010). Treatment of 
diabetic rats with EER at both the doses had 
reversed the activities of these enzymatic 
antioxidants. Therefore, it is reasonable to 
assume that EER treatment at both the 
doses improves the oxidative balance of 
kidney in diabetic rats, because EER 
treatment was able to reduce the level of 
TBARS and free radical generation. 
In conclusion, the present study demon-
strates that EER can be used to prevent 
progression of diabetic nephrotoxicity for 
the first time. Administration of EER 
improves renal function and ameliorates 
renal histopathological changes in HFD fed 
and low dose STZ-induced type 2 diabetic 
rat model; possibly by improvement in 
glucose and lipid metabolism, enhancement 
of insulin sensitivity, blood pressure 
lowering, and inhibition of lipid 
peroxidation process. Further investigation 
of this preventive effect of EER against 
diabetic nephrotoxicity may have a 
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considerable impact on developing clinical-
clinically feasible strategies to prevent or 
delay in progression of diabetic kidney 
injury. 
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